Open Access

Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model

Corrigendum in: /10.3892/ol.2023.13986

  • Authors:
    • Xiaoyi Liu
    • Jianxia Hu
    • Yueyun Li
    • Weihong Cao
    • Yu Wang
    • Zhongliang Ma
    • Funian Li
  • View Affiliations

  • Published online on: March 2, 2018     https://doi.org/10.3892/ol.2018.8166
  • Pages: 6265-6274
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Development of an improved breast cancer therapy has been an elusive goal of cancer gene therapy for a long period of time. Human mesenchymal stem cells derived from umbilical cord (hUMSCs) genetically modified with the interleukin (IL)‑18 gene (hUMSCs/IL‑18) were previously demonstrated to be able to suppress the proliferation, migration and invasion of breast cancer cells in vitro. In the present study, the effect of hUMSCs/IL‑18 on breast cancer in a mouse model was investigated. A total of 128 mice were divided into 2 studies (the early‑effect study and the late‑effect study), with 4 groups in each, including the PBS‑, hUMSC‑, hUMSC/vector‑ and hUMSC/IL‑18‑treated groups. All treatments were injected along with 200 µl PBS. Following therapy, the tumor size, histological examination, and expression of lymphocytes, Ki‑67, cluster of differentiation 31 and cytokines [interleukin (IL)‑18, IL‑12, interferon (IFN)‑γ and TNF‑α] in each group were analyzed. Proliferation of cells (assessed by measuring tumor size and Ki‑67 expression) and metastasis, (by determining pulmonary and hepatic metastasis) of breast cancer cells in the hUMSC/IL‑18 group were significantly decreased compared with all other groups. hUMSCs/IL‑18 suppressed tumor cell proliferation by activating immunocytes and immune cytokines, decreasing the proliferation index of proliferation marker protein Ki‑67 of tumor cells and inhibiting tumor angiogenesis. Furthermore, hUMSCs/IL‑18 were able to induce a more marked and improved therapeutic effect in the tumor sites, particularly in early tumors. The results of the present study indicate that hUMSCs/IL‑18 were able to inhibit the proliferation and metastasis of breast cancer cells in vivo, possibly leading to an approach for a novel antitumor therapy in breast cancer.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu X, Hu J, Li Y, Cao W, Wang Y, Ma Z and Li F: Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model Corrigendum in /10.3892/ol.2023.13986. Oncol Lett 15: 6265-6274, 2018.
APA
Liu, X., Hu, J., Li, Y., Cao, W., Wang, Y., Ma, Z., & Li, F. (2018). Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model Corrigendum in /10.3892/ol.2023.13986. Oncology Letters, 15, 6265-6274. https://doi.org/10.3892/ol.2018.8166
MLA
Liu, X., Hu, J., Li, Y., Cao, W., Wang, Y., Ma, Z., Li, F."Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model Corrigendum in /10.3892/ol.2023.13986". Oncology Letters 15.5 (2018): 6265-6274.
Chicago
Liu, X., Hu, J., Li, Y., Cao, W., Wang, Y., Ma, Z., Li, F."Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model Corrigendum in /10.3892/ol.2023.13986". Oncology Letters 15, no. 5 (2018): 6265-6274. https://doi.org/10.3892/ol.2018.8166